Health TrialsbyHealthPanel

Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

ConditionCentral Serous Chorioretinopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorHelse Stavanger HF

About this trial

Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Able to sign informed consent

Possible to obtain fundus imaging

Subfoveal presence of SRF on OCT

Present attack is 1st -3rd attack of CSC

Disqualifiers

History of retinal disease other than CSC (e.g. retinal detachment)

Contraindications for FA, ICGA or PDT (only for chronic CSC)

Trial population

Patients diagnosed with acute or chronic CSC.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Verteporfin

    Drug

    Chronic CSC are receiving one treatment before the observation period.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Acute0 interventions
Group B: Chronic1 intervention

Trial outcomes

Primary outcomes

1

Change in mean blur rate

Relative changes in choroidal blood flow

Time frame
6 months
2

Change in pulse wave form analysis

Changes in the shapes of pulse curves

Time frame
6 months

Secondary outcomes

1

Change in choroidal density

Changes in the tissue density

Time frame
6 months
2

Change in choroidal thickness

Changes in the morphology of the choroid

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Helse Stavanger HF

Lead sponsor

Source ClinicalTrials.gov
Apply now